CN114621919B - 一种增强间充质干细胞免疫调节能力的方法 - Google Patents
一种增强间充质干细胞免疫调节能力的方法 Download PDFInfo
- Publication number
- CN114621919B CN114621919B CN202210531798.7A CN202210531798A CN114621919B CN 114621919 B CN114621919 B CN 114621919B CN 202210531798 A CN202210531798 A CN 202210531798A CN 114621919 B CN114621919 B CN 114621919B
- Authority
- CN
- China
- Prior art keywords
- ascorbic acid
- cells
- factor
- culture
- mesenchymal stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 42
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 16
- 230000007365 immunoregulation Effects 0.000 title claims abstract description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 29
- 102000015696 Interleukins Human genes 0.000 claims abstract description 21
- 108010063738 Interleukins Proteins 0.000 claims abstract description 21
- 102000003390 tumor necrosis factor Human genes 0.000 claims abstract 6
- 210000004027 cell Anatomy 0.000 claims description 62
- 150000000996 L-ascorbic acids Chemical class 0.000 claims description 22
- 239000001963 growth medium Substances 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 10
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 claims description 7
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 5
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 108010082786 Interleukin-1alpha Proteins 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 3
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 102000004125 Interleukin-1alpha Human genes 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 23
- 230000004663 cell proliferation Effects 0.000 abstract description 6
- 230000005847 immunogenicity Effects 0.000 abstract description 6
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 32
- 102100040247 Tumor necrosis factor Human genes 0.000 description 26
- 230000002757 inflammatory effect Effects 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 11
- 230000028327 secretion Effects 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 102000000589 Interleukin-1 Human genes 0.000 description 8
- 108010002352 Interleukin-1 Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000038379 digestive enzymes Human genes 0.000 description 7
- 108091007734 digestive enzymes Proteins 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000001488 sodium phosphate Substances 0.000 description 7
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 7
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 6
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 6
- 101150094002 TWIST1 gene Proteins 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 5
- 239000012452 mother liquor Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000009758 senescence Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 101150098813 Ido1 gene Proteins 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 239000011692 calcium ascorbate Substances 0.000 description 2
- 229940047036 calcium ascorbate Drugs 0.000 description 2
- 239000002967 calcium-L-ascorbate Substances 0.000 description 2
- 235000005937 calcium-L-ascorbate Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102100031171 CCN family member 1 Human genes 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 101001060267 Homo sapiens Fibroblast growth factor 5 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 101150058514 PTGES gene Proteins 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 102100033076 Prostaglandin E synthase Human genes 0.000 description 1
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 101100451295 Takifugu rubripes hmox gene Proteins 0.000 description 1
- 102000006280 Twist-Related Protein 1 Human genes 0.000 description 1
- 108010083162 Twist-Related Protein 1 Proteins 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210531798.7A CN114621919B (zh) | 2022-05-17 | 2022-05-17 | 一种增强间充质干细胞免疫调节能力的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210531798.7A CN114621919B (zh) | 2022-05-17 | 2022-05-17 | 一种增强间充质干细胞免疫调节能力的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114621919A CN114621919A (zh) | 2022-06-14 |
CN114621919B true CN114621919B (zh) | 2022-12-06 |
Family
ID=81907256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210531798.7A Active CN114621919B (zh) | 2022-05-17 | 2022-05-17 | 一种增强间充质干细胞免疫调节能力的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114621919B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102936578A (zh) * | 2012-11-12 | 2013-02-20 | 山东省齐鲁干细胞工程有限公司 | 一种增强间充质干细胞免疫抑制功能的方法 |
WO2014093948A1 (en) * | 2012-12-14 | 2014-06-19 | Rutgers, The State University Of New Jersey | Methods modulating immunoregulatory effect of stem cells |
CN105985928A (zh) * | 2015-02-10 | 2016-10-05 | 睿尔(天津)生物科技有限公司 | 一种增强间充质干细胞免疫调节能力的预处理培养方法 |
CN110368402A (zh) * | 2019-08-09 | 2019-10-25 | 陕西佰傲干细胞再生医学有限公司 | 间充质干细胞制剂及其制备方法和应用 |
CN112656817A (zh) * | 2021-01-25 | 2021-04-16 | 朗姿赛尔生物科技(广州)有限公司 | 一种干细胞制剂及其在制备治疗肝损伤药物中的应用 |
-
2022
- 2022-05-17 CN CN202210531798.7A patent/CN114621919B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102936578A (zh) * | 2012-11-12 | 2013-02-20 | 山东省齐鲁干细胞工程有限公司 | 一种增强间充质干细胞免疫抑制功能的方法 |
WO2014093948A1 (en) * | 2012-12-14 | 2014-06-19 | Rutgers, The State University Of New Jersey | Methods modulating immunoregulatory effect of stem cells |
CN105008521A (zh) * | 2012-12-14 | 2015-10-28 | 罗格斯新泽西州立大学 | 调节干细胞的免疫调节作用的方法 |
CN105985928A (zh) * | 2015-02-10 | 2016-10-05 | 睿尔(天津)生物科技有限公司 | 一种增强间充质干细胞免疫调节能力的预处理培养方法 |
CN110368402A (zh) * | 2019-08-09 | 2019-10-25 | 陕西佰傲干细胞再生医学有限公司 | 间充质干细胞制剂及其制备方法和应用 |
CN112656817A (zh) * | 2021-01-25 | 2021-04-16 | 朗姿赛尔生物科技(广州)有限公司 | 一种干细胞制剂及其在制备治疗肝损伤药物中的应用 |
Non-Patent Citations (1)
Title |
---|
Ascorbic acid 2-glucoside stably promotes the primitiveness of embryonic and mesenchymal stem cells through TET- and CREB1- dependent mechanisms;Seungun Lee等;《Antioxidants and Redox Signaling》;20191206;第32卷(第1期);摘要,第12页最后1段,第13页最后1段到第14页第2段 * |
Also Published As
Publication number | Publication date |
---|---|
CN114621919A (zh) | 2022-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11339372B2 (en) | Serum-free medium inducing differentiation of umbilical cord mesenchymal stem cell into insulin-secretion-like cell and preparation method and use thereof | |
JP6648259B2 (ja) | 向上された臍帯由来付着型幹細胞、その製造方法及びその用途 | |
US20210322485A1 (en) | Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria | |
Liu et al. | Comparison of the biological characteristics of mesenchymal stem cells derived from bone marrow and skin | |
CN111826348B (zh) | 一种人诱导性多能干细胞来源的间充质干细胞体外高效制备方法和应用 | |
US20210275599A1 (en) | Mitochondrial augmentation therapy of brain diseases | |
JP2021531288A (ja) | 眼疾患のミトコンドリア増強療法 | |
WO2020021540A9 (en) | Mitochondrial augmentation therapy of pancreatic diseases | |
JP2021532095A (ja) | 肝臓疾患のミトコンドリア増強療法 | |
Reed et al. | Cultivation of anaerobes and oxidation-reduction potentials | |
EP2265708B1 (en) | Methods for stem cell production and therapy | |
Yuan et al. | Therapeutic potential of dental pulp stem cells and their derivatives: Insights from basic research toward clinical applications | |
Amiri et al. | Co-culture of mesenchymal stem cell spheres with hematopoietic stem cells under hypoxia: a cost-effective method to maintain self-renewal and homing marker expression | |
CN114621919B (zh) | 一种增强间充质干细胞免疫调节能力的方法 | |
Wang et al. | SHED‐derived exosomes improve the repair capacity and osteogenesis potential of hPDLCs | |
CN116218770B (zh) | 一种间充质干细胞的制备方法和应用 | |
WO2020021534A9 (en) | Mitochondrial augmentation therapy of renal diseases | |
TWI796536B (zh) | 包含克隆幹細胞的用於治療胰腺炎的藥學組合物 | |
CN112300992B (zh) | 一种nk细胞培养液及多级激活nk细胞的培养方法 | |
CN112076217A (zh) | 一种间充质干细胞来源的抗炎症氧化脂质组合物的制备方法 | |
CN104894059A (zh) | 一型硫氧还蛋白在内皮祖细胞的培养中的应用及内皮祖细胞的培养方法 | |
CN116590225B (zh) | 磷脂酰胆碱在制备促进猪FAPs细胞分化聚脂制剂中的应用 | |
CN117603909B (zh) | 高免疫抑制的UCMSCs及其培养方法、试剂与应用 | |
CN110904038B (zh) | 一种间充质干细胞及其应用 | |
CN115975920A (zh) | 一种清除衰老间充质干细胞的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 300452 building 20, Green Valley Health Industrial Park, No. 59, Kangtai Avenue, Binhai Science Park, high tech Zone, Binhai New Area, Tianjin Patentee after: Jiutian Lanyue Biotechnology (Tianjin) Co.,Ltd. Country or region after: China Address before: 300452 building 20, Green Valley Health Industrial Park, No. 59, Kangtai Avenue, Binhai Science Park, Binhai high tech Zone, Binhai New Area, Tianjin Patentee before: Tianjiu regenerative medicine (Tianjin) Technology Co.,Ltd. Country or region before: China |